TME-SW
01698
XIAOMI-W
01810
BOSS ZHIPIN-W
02076
TENCENT
00700
JD HEALTH
06618
(Q6)Sep 30, 2024 | (FY)Mar 31, 2024 | (Q6)Sep 30, 2023 | (FY)Mar 31, 2023 | (Q6)Sep 30, 2022 | (FY)Mar 31, 2022 | (Q6)Sep 30, 2021 | (FY)Mar 31, 2021 | (Q6)Sep 30, 2020 | (FY)Mar 31, 2020 | |
---|---|---|---|---|---|---|---|---|---|---|
Turnover | -4.49%1.09B | -4.28%2.15B | -2.05%1.14B | -5.43%2.24B | 4.49%1.16B | -0.08%2.37B | -0.78%1.11B | 9.55%2.37B | -0.04%1.12B | 0.17%2.17B |
Operating income | -4.49%1.09B | -4.28%2.15B | -2.05%1.14B | -5.43%2.24B | 4.49%1.16B | -0.08%2.37B | -0.78%1.11B | 9.55%2.37B | -0.04%1.12B | 0.17%2.17B |
Cost of sales | 8.49%-746.2M | 6.04%-1.51B | 2.39%-815.4M | 5.49%-1.61B | -3.15%-835.4M | -3.38%-1.7B | -5.65%-809.9M | -9.57%-1.65B | 1.63%-766.6M | 1.55%-1.5B |
Operating expenses | 8.49%-746.2M | 6.04%-1.51B | 2.39%-815.4M | 5.49%-1.61B | -3.15%-835.4M | -3.38%-1.7B | -5.65%-809.9M | -9.57%-1.65B | 1.63%-766.6M | 1.55%-1.5B |
Gross profit | 5.53%343.5M | 0.19%634.9M | -1.18%325.5M | -5.29%633.7M | 8.04%329.4M | -7.91%669.1M | -14.59%304.9M | 9.49%726.6M | 3.54%357M | 4.27%663.6M |
Selling expenses | -12.25%-149.4M | 5.31%-278.4M | 11.68%-133.1M | 3.57%-294M | -11.88%-150.7M | -3.18%-304.9M | 0.37%-134.7M | 0.27%-295.5M | 2.38%-135.2M | -0.78%-296.3M |
Administrative expenses | -12.85%-44.8M | -0.39%-77.9M | -2.85%-39.7M | -2.65%-77.6M | -3.76%-38.6M | 8.59%-75.6M | 7.92%-37.2M | -15.18%-82.7M | -3.06%-40.4M | 7.83%-71.8M |
Research and development expenses | -9.29%-45.9M | 1.92%-81.7M | 0.71%-42M | 1.19%-83.3M | 0.70%-42.3M | 2.43%-84.3M | -2.16%-42.6M | -5.75%-86.4M | -2.46%-41.7M | -5.83%-81.7M |
Special items of operating profit | 300.00%800K | -141.18%-700K | -133.33%-400K | 440.00%1.7M | 200.00%1.2M | -111.90%-500K | -86.21%400K | -28.81%4.2M | -65.88%2.9M | 0.00%5.9M |
Operating profit | -5.53%104.2M | 8.70%196.2M | 11.41%110.3M | -11.43%180.5M | 9.03%99M | -23.44%203.8M | -36.33%90.8M | 21.17%266.2M | 5.71%142.6M | 13.72%219.7M |
Financing cost | 70.00%-900K | 59.17%-4.9M | 47.37%-3M | -25.00%-12M | -18.75%-5.7M | -31.51%-9.6M | -41.18%-4.8M | 1.35%-7.3M | -6.25%-3.4M | -722.22%-7.4M |
Share of profits of associates | --100K | ---- | ---- | ---- | ---- | 0.00%400K | 200.00%300K | --400K | --100K | ---- |
Earning before tax | -3.63%103.4M | 13.53%191.3M | 15.01%107.3M | -13.41%168.5M | 8.11%93.3M | -24.95%194.6M | -38.05%86.3M | 22.14%259.3M | 5.77%139.3M | 10.40%212.3M |
Tax | -16.79%-16M | -27.98%-24.7M | -21.24%-13.7M | 11.87%-19.3M | -20.21%-11.3M | 22.89%-21.9M | 40.13%-9.4M | -31.48%-28.4M | -14.60%-15.7M | -2.86%-21.6M |
After-tax profit from continuing operations | -6.62%87.4M | 11.66%166.6M | 14.15%93.6M | -13.61%149.2M | 6.63%82M | -25.21%172.7M | -37.78%76.9M | 21.08%230.9M | 4.75%123.6M | 11.33%190.7M |
Earning after tax | -6.62%87.4M | 11.66%166.6M | 14.15%93.6M | -13.61%149.2M | 6.63%82M | -25.21%172.7M | -37.78%76.9M | 21.08%230.9M | 4.75%123.6M | 11.33%190.7M |
Profit attributable to shareholders | -6.62%87.4M | 11.66%166.6M | 14.15%93.6M | -13.61%149.2M | 6.63%82M | -25.21%172.7M | -37.78%76.9M | 21.08%230.9M | 4.75%123.6M | 11.33%190.7M |
Basic earnings per share | -6.49%0.346 | 11.68%0.66 | 13.85%0.37 | -13.72%0.591 | 6.56%0.325 | -25.22%0.685 | -37.76%0.305 | 21.00%0.916 | 4.48%0.49 | 11.00%0.757 |
Diluted earnings per share | -6.49%0.346 | 11.51%0.659 | 13.85%0.37 | -13.72%0.591 | 6.56%0.325 | -25.22%0.685 | -37.76%0.305 | 21.00%0.916 | 4.48%0.49 | 11.16%0.757 |
Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
Accounting Standards | IAS | IAS | IAS | IAS | IAS | IAS | IAS | IAS | IAS | IAS |
Audit Opinions | -- | Unqualified Opinion | -- | Unqualified Opinion | -- | Unqualified Opinion | -- | Unqualified Opinion | -- | Unqualified Opinion |
Auditor | -- | KPMG | -- | KPMG | -- | KPMG | -- | KPMG | -- | KPMG |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.